# Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

> **NCT03575325** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 11 (actual)

## Conditions studied

- Lymphoid Leukemia
- Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Relapsed Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** CPX-351

## Key facts

- **NCT ID:** NCT03575325
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2021-06-07
- **Final completion:** 2023-09-14
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575325, "Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03575325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*